The Fred Hutch Biostatistics Program hosts seminars featuring presentations by Hutch and outside scientists to share their latest developments and recent research. Each seminar includes an hour-long presentation and discussion during which speakers showcase their work and findings.

This seminar will be held on Zoom due to the COVID-19 pandemic.

Lung cancer is one of the most common cancers worldwide and the leading cause of cancer deaths both globally and in the United States. The National Lung Cancer Screening Trial showed annual screening by low-dose computed tomography (LDCT) reduced mortality and in 2013 the US Preventative Services Task Force recommended screening by LDCT for high-risk smokers. A predictive model for 6-year risk of lung cancer was developed using results of the Prostate, Lung, Colon, and Ovarian Cancer Screening Trial (PLCOm2012) and put forth as selection criteria for referral to screening. The Hanash Lab at MD Anderson has established and validated a panel of four circulating protein biomarkers (4MP) for lung cancer risk assessment. In this talk, I will describe joint work with Ziding Feng and the Hanash lab leading to a definitive validation of the 4MP using preclinical specimens from the PLCO biorepository, highlight validation of selection criteria based on combining the 4MP with PLCOm2012, and discuss next steps for investigating the clinical utility of a biomarker-based strategy for referral to LDCT screening.